AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer
David S. Hong(The University of Texas MD Anderson Cancer Center), A. Robert MacLeod(Ionis Pharmaceuticals (United States)), Samantha J. Lee(Ionis Pharmaceuticals (United States)), Xiaokun Xiao(Ionis Pharmaceuticals (United States)), Richard Woessner(AstraZeneca (United States)), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Corinne Reimer(AstraZeneca (United States)), Nathan Fowler(Repligen (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Morvarid Mohseni(Bristol-Myers Squibb (United States)), Minji Jo(Japanese Foundation For Cancer Research), Razelle Kurzrock(Medical College of Wisconsin), John Nemunaitis(Gradalis (United States)), Joanna Schmidt(Ionis Pharmaceuticals (United States)), Mason Yamashita(Ionis Pharmaceuticals (United States)), Anas Younes(Intercept Pharmaceuticals (United States)), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Deborah Lawson(AstraZeneca (United States)), Youngsoo Kim(Ionis Pharmaceuticals (United States)), Tianyuan Zhou(Ionis Pharmaceuticals (United States)), Murali V.P. Nadella(AstraZeneca (South Korea)), Alexey S. Revenko(Ionis Pharmaceuticals (United States)), David C. Blakey(Unknown), Jeff Hsu(Ionis Pharmaceuticals (United States))
Cited by 438
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k